Skip to main content

Indiana Hemorrhagic Stroke Meeting to explore new surgical options for deadly strokes


INDIANAPOLIS – The Indiana Clinical and Translational Sciences Institute will sponsor the inaugural Indiana Hemorrhagic Stroke Meeting on Tuesday, June 30, at the JW Marriott in Indianapolis.

The meeting will bring together neurosurgeons, neurologists, stroke specialists, nurses, stroke care support teams and chief medical officers to learn about new opportunities for treating intracerebral hemorrhage, also known as hemorrhagic stroke, the most deadly form of stroke. The attendees will discuss recent clinical evidence indicating that early surgical intervention of hemorrhagic stroke using new access technology can mitigate brain injury and result in a faster, more complete recovery. This offers new hope for hemorrhagic stroke patients who may have had no surgical options before.

“What we are seeing in the peer-reviewed clinical evidence is truly groundbreaking for the appropriate patients who had very little to be optimistic about before when suffering a hemorrhagic stroke,” said Anantha Shekhar, M.D., Ph.D., director of the Indiana Clinical and Translation Sciences Institute. “Bringing together these well-respected thought leaders from across the spectrum of neurology, neurosurgical and neuro critical care and sharing our experiences with the goal of impacting clinical outcomes of this disease is a unique effort and a monumental step in the right direction.”

Five health care organizations are supporting the educational event, including Indiana CTSI, Eskenazi Health, St. Vincent Neuroscience Institute, Franciscan St. Francis Health and Goodman Campbell Brain and Spine. Speaking at the event will be a multi-disciplinary team that includes Mitesh Shah, M.D., president of Goodman Campbell Brain and Spine; Ronald Young, M.D., neurosurgeon, and Jeffrey Hilburn, M.D., neurologist, both from St. Vincent Indianapolis Hospital; and Jonathan Ratcliff, assistant professor of emergency medicine and neurology at Emory University School of Medicine in Atlanta.

More than 100,000 hemorrhagic strokes occur each year in the United States. It is the deadliest class of stroke, with an early mortality rate of 32 to 50 percent. Despite the severity of hemorrhagic strokes, 95 percent of cases are medically managed, meaning patients are provided medications to reduce swelling or minimize the bleed. A surgical approach has not been a viable option due to associated risks with that particular type of bleed. For that reason, 80 percent of those who survive medical management of the bleed are left significantly disabled in speech, motor skills and cognitive functions.

The Indiana Hemorrhagic Stroke Meeting will provide a look at peer-reviewed evidence and in-depth education on the new concepts, technologies and techniques for operating on hemorrhagic stroke that are being successfully implemented throughout the country. The meeting will identify major advances in key areas of recent research and technology in hemorrhagic stroke care and provide an overview of the fundamentals involved with new approaches. A hands-on lab showcasing novel technologies will also be featured, including a live demonstration of the new approach for intracerebral clot evacuation using access technology called the NICO BrainPath.

Recently published clinical data on utilization of the BrainPath for ICH can be found here:
International Stroke Conference Study Results

For more information about the 1st Annual Indiana Hemorrhagic Stroke Meeting: 2015 Indiana Hemorrhagic Stroke Meeting

About CTSI:
The Indiana Clinical and Translational Sciences Institute (CTSI) is a statewide collaboration of Indiana University, Purdue University and the University of Notre Dame, as well as public and private partnerships, which facilitates the translation of scientific discoveries in the lab into clinical trials and new patient treatments in Indiana and beyond. Established in 2008, the Indiana CTSI is supported by a $25 million Clinical and Translational Science Award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health, supplemented by nearly $60 million from the state, the three member universities, and public and private partnerships. The Indiana CTSI is a member of a national network of 61 CTSA-funded organizations across the U.S.

About the NICO BrainPath Technology:
The patented NICO BrainPath technology enables a transsulcal surgical approach to atraumatically access the brain through an opening smaller than a dime. The integrated approach using BrainPath is designed to minimize damage to surrounding tissue. This is accomplished by accessing these regions by using the natural folds in the brain as a corridor to navigate to an abnormality. Surgeons are able to remove the abnormality from the brain in a less traumatic way through this narrow corridor. More than 200 neurosurgeons are now trained on this integrated approach using BrainPath at more than 53 hospitals across the country. More than 1,600 BrainPath procedures have been performed to date. To learn more about BrainPath, visit